Skip to main content

Table 1 Clinical characteristics of the study population

From: Effect of erythropoietin-stimulating agent on uremic inflammation

Age, years

65.5 ± 13.7

Male sex (%)

611 (67.9)

BMI, kg/m2

23.0 ± 4.0

SBP, mmHg

153 ± 26

DBP, mmHg

78 ± 15

CTR, %

54 ± 7

Primary disease

 

Chronic glomeruronephritis

226 (25.1)

Diabetic nephropathy

432 (48.0)

Glomerulosclerosis

104 (11.6)

Polycystic kidney disease

28 (3.1)

Post-renal disease

5 (0.6)

Others

105 (11.6)

Duration of nephrologist care, months

33 ± 43

WBC, /mm3

6160 ± 1270

Hemoglobin, g/dL

8.5 ± 1.5

Plt x 104, mm3

19.4 ± 7.1

Albumin, g/dL

3.3 ± 0.6

LDL-C, mg/dL

98 ± 41

HDL-C, mg/dL

47 ± 17

Creatinin, mg/dL

9.5 ± 3.5

BUN, mg/dL

89 ± 27

Uric acid, mg/dL

8.6 ± 2.2

eGFR, mL/min/1.73 m2

5.4 ± 2.9

Calcium, mg/dL

7.8 ± 1.0

Phosphate, mg/dL

6.0 ± 1.6

Intact-PTH, pg/mL

304 ± 214

CRP, mg/dL

0.48 ± 0.68

HCO3-, mmol/L

18.9 ± 5.0

ESA (%)

614 (68.2)

ESA dose, u/month

17813 ± 6580

ARB (%)

489 (54.3)

ACE-I (%)

165 (16.3)

ARB or ACE-I (%)

541 (60.1)

ARB and ACE-I (%)

113 (12.6)

CCB (%)

565 (62.8)

other anti-HT drugs (%)

315 (35.0)

Vitamin D (%)

174 (19.3)

Calcium agents (%)

271 (30.1)

Iron agents (%)

85 (9.4)

AST-120 (%)

160 (17.8)

  1. BMI; body mass index, SBP; systolic blood pressure, DBP; diastolic blood pressure, CTR; Cardiothoracic ratio, WBC; white blood cell, Plt; platelets, LDL-C; low density lipoprotein cholesterol, HDL-C; high density lipoprotein cholesterol, BUN; blood urea nitrogen, eGFR; estimated glomerular filtration rate, PTH; parathyroid hormone, CRP; C-reactive protein, ESA; erythropoietin-stimulating agents, ARB; angiotensin-II receptor blockers, ACE-I; angiotensin-converting enzyme inhibitors, CCB; calcium channel blockers, anti-HT; antihypertensive.